Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Lynda Heaphy

Nurse Practitioner, Family Phoenix, AZ Nurse Practitioner

NPI 1952309387 CMS profile 10492194

2550 W Union Hills Dr Ste 390, Phoenix, AZ 85027

Open in the dashboard

General payments

$13,705

631 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lynda Heaphy of Phoenix, AZ is reported in the CMS Open Payments database as having received $13,705 across 631 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,030 46
2024 General $3,857 175
2023 General $3,601 156
2022 General $2,834 135
2021 General $2,383 119

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lynda Heaphy
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Lynda Heaphy were reported at $1,030. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Lynda Heaphy Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $2,383 $124 $35–$379 $132
2022 $2,834 $141 $44–$430 $149
2023 $3,601 $154 $49–$476 $160
2024 $3,857 $165 $51–$504 $164
2025 $1,030 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $1,970 80 payments
  2. GlaxoSmithKline, LLC. $1,694 107 payments
  3. Genzyme Corporation $1,618 63 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $1,254 52 payments
  5. Regeneron Healthcare Solutions, Inc. $725 24 payments
  6. United Therapeutics Corporation $619 29 payments
  7. Actelion Pharmaceuticals US, Inc. $545 17 payments
  8. Mylan Specialty L.P. $519 22 payments
  9. Genentech USA, Inc. $385 16 payments
  10. Insmed, Inc. $360 18 payments
  11. Other $4,017 203 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $13,412 627 payments
  2. Education $293 4 payments
Products named General payments · program years 2021–2025
  1. DUPIXENT Immunology $1,829 69 payments
  2. TRELEGY ELLIPTA $920 64 payments
  3. NUCALA $859 50 payments
  4. FASENRA $858 19 payments
  5. TEZSPIRE $803 21 payments
  6. DUPIXENT Inflammation And Immunology $656 22 payments
  7. OFEV $637 24 payments
  8. YUPELRI $564 24 payments
  9. SPIRIVA RESPIMAT $540 25 payments
  10. OPSUMIT $525 16 payments
  11. Other $8,444 384 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 57 drugs

Part D claims

5,970

Median for Nurse Practitioner: 389

Drug cost

$2,639,129

Median for Nurse Practitioner: $21,885

Branded share of claims

70.9%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ofev Nintedanib Esylate Brand 54 $713,758
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 743 $655,476
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 327 $238,129
Breo Ellipta Fluticasone/Vilanterol Brand 241 $120,888
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 176 $101,870
Xolair Omalizumab Brand 34 $99,313
Tezspire Tezepelumab-Ekko Brand 20 $94,350
Spiriva Handihaler Tiotropium Bromide Brand 101 $70,983
Symbicort Budesonide/Formoterol Fumarate Brand 242 $70,501
Spiriva Respimat Tiotropium Bromide Brand 77 $61,952

The 10 drugs with the highest cost, of 57 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 17 billing codes

Paid by Medicare

$108,396

Medicare's payments for the services billed

Medicare patients

599

Average age 74

Services billed

1,427

324 women, 275 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 59%
COPD 49%
Ischemic heart disease 41%
Diabetes 34%
Chronic kidney disease 32%
Atrial fibrillation 26%
Depression 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 26 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
$805 — —
TEZSPIRE
$257 20 —
YUPELRI
$212 — —
TRELEGY ELLIPTA
$190 743 —
Sunosi
$185 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 26 with Patron

Records

631 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record